Scholtz & Company’s Apyx Medical APYX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.5K Hold
10,000
– – 0.01% 45
2026
Q2
$44.9K Hold
10,000
– – 0.02% 48
2026
Q1
$36.9K Sell
10,000
-10,000
-50% -$37.4K 0.02% 49
2025
Q4
$70K Hold
20,000
– – 0.03% 51
2025
Q3
$42.8K Hold
20,000
– – 0.02% 51
2025
Q2
$45K Hold
20,000
– – 0.02% 52
2025
Q1
$27.4K Hold
20,000
– – 0.01% 51
2024
Q4
$31.6K Hold
20,000
– – 0.02% 48
2024
Q3
$24.8K Hold
20,000
– – 0.01% 51
2024
Q2
$26.8K Hold
20,000
– – 0.01% 50
2024
Q1
$27.2K Hold
20,000
– – 0.01% 50
2023
Q4
$52K Hold
20,000
– – 0.03% 66
2023
Q3
$64K Buy
20,000
+5,000
+33% +$23.3K 0.04% 40
2023
Q2
$75K Buy
15,000
+5,000
+50% +$25.3K 0.05% 38
2023
Q1
$29K Buy
+10,000
New +$29.2K 0.02% 34

Other funds holding APYX

Scholtz & Company's APYX Position: Q3 2026 in Review

Scholtz & Company held its Apyx Medical (APYX) position steady in Q3 2026 at 10,000 shares worth $24.5K. The position accounts for 0.01% of the portfolio, ranked #45.

Scholtz & Company first reported a position in APYX in Q1 2023 and has held it in 15 quarters since. The position peaked at $75K in Q2 2023. 68 funds tracked by Wall St. Rank hold APYX as of Q3 2026.

  • Scholtz & Company held 10,000 shares of Apyx Medical worth $24.5K as of Q3 2026.
  • Scholtz & Company left its Apyx Medical share count unchanged in Q3 2026.
  • Apyx Medical made up 0.01% of Scholtz & Company's portfolio in Q3 2026, its #45 holding.
  • Scholtz & Company first reported a position in Apyx Medical in Q1 2023 and has held it in 15 quarters since.
  • Scholtz & Company's Apyx Medical position peaked at $75K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Apyx Medical as of Q3 2026.

Based on Scholtz & Company's 13F filing for Q3 2026, filed 9 Nov 2026.